Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion type Assertion NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_head.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion description "[However, these differences are unclear in resectable primary lung tumors.The clinicopathological features of 88 (20.9%) Ex19, 124 (29.4%) Ex21, and 198 (46.9%) EGFR wild-type (Wt) clinical stage I primary adenocarcinomas resected between January 1, 2012 and October 31, 2014 were compared by using Chi-square tests, residual error analysis, analysis of variance, and Tukey tests.Ex21 lesions occurred more frequently in women and never-smokers and had a higher tumor disappearance rate (TDR: 59.6% vs 43.9%; P < 0.001) and lower maximum standardized uptake value (maxSUV: 2.0 vs 3.5; P < 0.01) than Wt lesions; Ex19 lesions had intermediate values (52.8% and 2.6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_provenance.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion evidence source_evidence_literature NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_provenance.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion SIO_000772 26496308 NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_provenance.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion wasDerivedFrom befree-2016 NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_provenance.
- NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_assertion wasGeneratedBy ECO_0000203 NP1295206.RAWsYyFI9BLkwqSujuP2bxOKpNv743FsRVHDPWkNsQojw130_provenance.